Immune checkpoint inhibitors (ICIS), such as PD-1/PD-L1 antibodies, have changed the way many cancers are treated (33).Studies have shown that cells of the immune system are rich in the tumor microenvironment in BC regardless of subtypes, higher rates of pathological complete response were reflected in neoadjuvant chemotherapy (34–36). The gene discussed is CD274; the disease is breast cancer.